Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition
- PMID: 24907870
- DOI: 10.1007/s00395-014-0421-1
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition
Abstract
Impaired nitric oxide (NO)-soluble guanylate cyclase (sGC)-cGMP signaling is involved in the pathogenesis of ischemic heart diseases, yet the impact of long-term sGC activation on progressive cardiac remodeling and heart failure after myocardial infarction (MI) has not been explored. Moreover, it is unknown whether stimulating the NO/heme-independent sGC provides additional benefits to ACE inhibition in chronic ischemic heart failure. Starting 10 days after MI, rats were treated with placebo, the sGC activator ataciguat (10 mg/kg/twice daily), ramipril (1 mg/kg/day), or a combination of both for 9 weeks. Long-term ataciguat therapy reduced left ventricular (LV) diastolic filling pressure and pulmonary edema, improved the rightward shift of the pressure-volume curve, LV contractile function and diastolic stiffness, without lowering blood pressure. NO/heme-independent sGC activation provided protection over ACE inhibition against mitochondrial superoxide production and progressive fibrotic remodeling, ultimately leading to a further improvement of cardiac performance, hypertrophic growth and heart failure. We found that ataciguat stimulating sGC activity was potentiated in (myo)fibroblasts during hypoxia-induced oxidative stress and that NO/heme-independent sGC activation modulated fibroblast-cardiomyocyte crosstalk in the context of heart failure and hypoxia. In addition, ataciguat inhibited human cardiac fibroblast differentiation and extracellular matrix protein production in response to TGF-β1. Overall, long-term sGC activation targeting extracellular matrix homeostasis conferred cardioprotection against progressive cardiac dysfunction, pathological remodeling and heart failure after myocardial infarction. NO/heme-independent sGC activation may prove to be a useful therapeutic target in patients with chronic heart failure and ongoing fibrotic remodeling.
Similar articles
-
Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure.Pharmacol Res. 2010 Nov;62(5):432-8. doi: 10.1016/j.phrs.2010.06.008. Epub 2010 Jun 22. Pharmacol Res. 2010. PMID: 20600916
-
Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress.Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1763-71. doi: 10.1152/ajpheart.51.2008. Epub 2008 Aug 29. Am J Physiol Heart Circ Physiol. 2008. PMID: 18757489
-
NO- and haem-independent soluble guanylate cyclase activators.Handb Exp Pharmacol. 2009;(191):309-39. doi: 10.1007/978-3-540-68964-5_14. Handb Exp Pharmacol. 2009. PMID: 19089335 Review.
-
Pentaerythritol Tetranitrate Targeting Myocardial Reactive Oxygen Species Production Improves Left Ventricular Remodeling and Function in Rats With Ischemic Heart Failure.Hypertension. 2015 Nov;66(5):978-87. doi: 10.1161/HYPERTENSIONAHA.115.05931. Epub 2015 Sep 8. Hypertension. 2015. PMID: 26351025
-
Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.Cardiovasc Drug Rev. 2007 Spring;25(1):30-45. doi: 10.1111/j.1527-3466.2007.00003.x. Cardiovasc Drug Rev. 2007. PMID: 17445086 Review.
Cited by
-
Capillary hemodynamics and contracting skeletal muscle oxygen pressures in male rats with heart failure: Impact of soluble guanylyl cyclase activator.Nitric Oxide. 2022 Feb 1;119:1-8. doi: 10.1016/j.niox.2021.12.001. Epub 2021 Dec 4. Nitric Oxide. 2022. PMID: 34871799 Free PMC article.
-
Ameliorating diabetes-associated atherosclerosis and diabetic nephropathy through modulation of soluble guanylate cyclase.Front Cardiovasc Med. 2023 Jul 12;10:1220095. doi: 10.3389/fcvm.2023.1220095. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37502180 Free PMC article.
-
Vasorelaxing effects of the soluble guanylyl cyclase activator BAY 60-2770 in nitrate-tolerant monkey and canine coronary arteries.Naunyn Schmiedebergs Arch Pharmacol. 2015 Mar;388(3):381-5. doi: 10.1007/s00210-014-1083-0. Epub 2015 Jan 13. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 25582420
-
Key inflammatory mechanisms underlying heart failure.Herz. 2019 Apr;44(2):96-106. doi: 10.1007/s00059-019-4785-8. Herz. 2019. PMID: 30715565 Free PMC article. Review.
-
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy.Eur Heart J. 2022 Feb 12;43(7):683-697. doi: 10.1093/eurheartj/ehab757. Eur Heart J. 2022. PMID: 34849696 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous